nach oben

Investigational New Drugs

Erschienen in:

13.10.2023 | Case Report

Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation

verfasst von: Yujie Cui, Jinlong Liang, Xiyun Kang, Miaomiao Liu, Qi Zhang, Hongzhen Zhang

Erschienen in: Investigational New Drugs | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Pulmonary enteric adenocarcinoma (PEAC) is a rare lung adenocarcinoma with morphological and immunohistochemical similarities to colorectal adenocarcinoma and intestinal differentiation. PEAC belongs to the group of non-small-cell lung carcinoma (NSCLC) and is defined as having a more than 50% intestinal differentiation component. We report a postoperative (T4N2M0 stage IIIb) PEAC patient with EGFR L858R + A871G combined mutation. Following surgery, the patient underwent treatment with the first-generation EGFR-TKI, gefitinib, and achieved an impressive 5-year progression-free survival (PFS). This suggests that gefitinib may serve as an effective treatment option for PEAC patients with EGFR L858R + A871G compound mutations.

Siegel RL, Miller KD, Jemal A, Cancer statistics (2020) CA Cancer J Clin. 2020 Jan;70(1):7–30

Li H, Cao W (2020 Jun) Pulmonary enteric adenocarcinoma: a literature review. J Thorac Dis 12(6):3217–3226

Gong J, Fan Y, Lu H (2021 Aug) Pulmonary enteric adenocarcinoma. Transl Oncol 14(8):101123

Guo Y, Song J, Wang Y, Huang L, Sun L, Zhao J, Zhang S, Jing W, Ma J, Han C (2020) Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-Mutant Non-small Cell Lung Cancer: a review. Front Oncol 10:610923CrossRefPubMedPubMedCentral

Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha MJ, Cross JB, Gray JE, Heymach JV (2021) Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 597(7878):732–737CrossRefPubMedPubMedCentral

Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS, Costa DB (2013) Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8:45–51CrossRefPubMedPubMedCentral

Jin LL, Wu ZZ, Wang YL, Chen DS, Li S, Xiao M, Zhao X (2021) Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation. Invest New Drugs 39(5):1419–1421CrossRefPubMed

Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, Song Y, Wu YL, Xu N, Zhou J, Luo R, Bai C, Jin Y, Liu W, Wei Z, Tan F, Wang Y, Ding L, Dai H, Jiao S, Wang J, Liang L, Zhang W, Sun Y (2013) Icotinib versus Gefitinib in previously treated advanced non-small-cell Lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 14(10):953–961CrossRefPubMed

Liu Y, Wang H, Yang S, Yang Y, Wu Y, He Z, Ma S, Mo Y, Chen H, Wang Q, Ge H (2022 Jun) EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors. J Thorac Dis 14(6):2254–2267

10.

Kamath A, Joseph AM, Gupta K, Behera D, Jaiswal A, Dewan R, Rajala MS (2015) Proteomic analysis of HEK293 cells expressing non small cell lung carcinoma associated epidermal growth factor receptor variants reveals induction of heat shock response. Exp Hematol Oncol 4:16CrossRefPubMedPubMedCentral

11.

Fu J, Tong Y, Xu Z, Li Y, Zhao Y, Wang T, Li C, Cang S (2023) Impact of TP53 mutations on EGFR-Tyrosine kinase inhibitor efficacy and potential treatment strategy. Clin Lung Cancer 24(1):29–39CrossRefPubMed

Titel: Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation
verfasst von: Yujie Cui
Jinlong Liang
Xiyun Kang
Miaomiao Liu
Qi Zhang
Hongzhen Zhang
Publikationsdatum: 13.10.2023
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 6/2023
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-023-01401-3

Springer Medizin

Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2023

Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1–3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial

Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer

Gastrointestinal signet ring cell malignancy: current advancement and future prospects

Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.

Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States

Antitumor activity of the new tyrphostin briva against BRAFV600E-mutant colorectal carcinoma cells

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Update Onkologie